Showing posts with label Bio-Technology. Show all posts
Showing posts with label Bio-Technology. Show all posts

Geminin: negative control of replication

{ Posted on 11:41 AM by rain }
Geminin: negative control of replication

G2 nuclei also contain at least one protein — called geminin — that prevents assembly of MCM proteins on freshly-synthesized DNA (probably by blocking the actions of Cdt1).

As the cell completes mitosis, geminin is degraded so the DNA of the two daughter cells will be able to respond to licensing factors and be able to replicate their DNA at the next S phase.

Gene therapy

{ Posted on 11:39 AM by rain }
Gene therapy
Main article: Gene therapy
Gene therapy using an Adenovirus vector. A new gene is inserted into an adenovirus vector, which is used to introduce the modified DNA into a human cell. If the treatment is successful, the new gene will make a functional protein.

Gene therapy may be used for treating, or even curing, genetic and acquired diseases like cancer and AIDS by using normal genes to supplement or replace defective genes or to bolster a normal function such as immunity. It can be used to target somatic (i.e., body) or gametes (i.e., egg and sperm) cells. In somatic gene therapy, the genome of the recipient is changed, but this change is not passed along to the next generation. In contrast, in germline gene therapy, the egg and sperm cells of the parents are changed for the purpose of passing on the changes to their offspring.

There are basically two ways of implementing a gene therapy treatment:

1. Ex vivo, which means “outside the body” – Cells from the patient’s blood or bone marrow are removed and grown in the laboratory. They are then exposed to a virus carrying the desired gene. The virus enters the cells, and the desired gene becomes part of the DNA of the cells. The cells are allowed to grow in the laboratory before being returned to the patient by injection into a vein.
2. In vivo, which means “inside the body” – No cells are removed from the patient’s body. Instead, vectors are used to deliver the desired gene to cells in the patient’s body.

As of June 2001, more than 500 clinical gene-therapy trials involving about 3,500 patients have been identified worldwide. Around 78% of these are in the United States, with Europe having 18%. These trials focus on various types of cancer, although other multigenic diseases are being studied as well. Recently, two children born with severe combined immunodeficiency disorder (“SCID”) were reported to have been cured after being given genetically engineered cells.

Bio-Technology General - BTGC- Profile

{ Posted on 11:38 AM by rain }
Bio-Technology General Corp. The Group's principal activity is to conduct research, development, manufacture and marketing of biopharmaceutical products. The Group through the internal research, development and agreement has a portfolio of therapeutic products. The products include OXANDRIN (r), BIO-TROPINTM, BIOLON (r), DELATESTRYL (r), MIRCETTE (r) and others. OXANDRIN(R) is used for the treatment of weight loss due to severe trauma, chronic inflection, extensive surgery or unknown pathophysiology. BIO-TROPIN(TM) for the treatment of growth hormone deficiency in children or turner syndrome. BIOLON (R) is used for the protection of the corneal endothelium during ophthalmic surgery. DELATESTRYL (R), for the treatment of hypogonadism and delayed puberty. On 30-Sep-2002, it acquired Rosemont Pharmaceuticals Ltd. During the year 2001, the Group acquired Myelos Corporation. Product sales accounted for 97% of 2002 revenues; Contract fees, 2% and Other revenues, 1%.

...